Apnimed to Participate in the 7th Annual Evercore HealthCONx Conference

News provided by

Nov 21, 2024, 08:00 ET

CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that Larry Miller, M.D., the company's Chief Executive Officer, will be participating in a fireside chat at the 7^th Annual Evercore HealthCONx Conference, which takes place December 3-5, 2024, in Coral Gables, FL.

Details of Apnimed's participation are as follows:

Event: Evercore 7^th Annual HealthCONx Conference
Format: Fireside Chat
Date: Wednesday, December 4, 2024
Time: 8:20 AM ET

Apnimed's presentation will be available via live webcast here, and will also be available on the "Events" page on the company's website for 90 days following the conference.

Apnimed will also be hosting 1x1 investor meetings on Tuesday, December 3, 2024, and Wednesday December 4, 2024. Investors interested in meeting with Apnimed at the conference should contact their Evercore representative directly.

About Apnimed
Apnimed is a pharmaceutical company dedicated to breathing new life into the sleep-related breathing disease treatment landscape. The company envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and elevate the health and expectations of everyone in the sleep-related breathing disease community. Based in Cambridge, Mass., Apnimed is advancing a focused pipeline of oral pharmaceutical product candidates designed to help improve oxygenation for people living with obstructive sleep apnea and beyond, to other sleep-related breathing diseases, including several that are part of our joint venture with Shionogi & Co., Ltd, Shionogi Apnimed Sleep Science (SASS). Learn more at apnimed.com or follow us on X and LinkedIn.

Media Contact:
[email protected]

Investor Contact:
Brian Ritchie
[email protected]

SOURCE Apnimed, Inc.